Abstract
Opioid-induced hyperalgesia (OIH) is defined as a state of nociceptive sensitisation caused by exposure to opioids. The condition is characterised by a paradoxical response whereby a patient receiving opioids for the treatment of pain could actually become more sensitive to certain painful stimuli. The type of pain experienced might be the same as the underlying pain or might be different from the original underlying pain.
Observational, cross-sectional, and prospective controlled trials have examined the expression and potential clinical significance of OIH in humans. Most studies have been conducted using several distinct cohorts and methodologies utilising former opioid addicts on methadone maintenance therapy, perioperative exposure to opioids in patients undergoing surgery, cancer patients on opioids, and healthy human volunteers after acute opioid exposure using human experimental pain testing.
There are several proposed mechanisms for OIH; among these mechanisms involving the central glutaminergic system, spinal dynorphins, descending facilitation, genetic mechanisms, and decreased reuptake and enhanced nociceptive response have been described as the important mechanisms.
Clinicians should suspect OIH when opioid treatment’s effect seems to wane in the absence of disease progression, particularly if found in the context of unexplained pain reports or diffuse allodynia unassociated with the original pain, and increased levels of pain with increasing dosages. The treatment involves reducing the opioid dosage, tapering them off, or supplementation with NMDA receptor inhibitors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-malignant pain: an epidemiological study. Pain. 2006;125:172–9.
Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik S, Portnoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131–46.
Kayan S, Woods LA, Mitchell CL. Morphine-induced hyperalgesia in rats tested on the hot plate. J Pharmacol Exp Ther. 1971;177(3):509–13.
Andrews HL. The effect of opiates on the pain threshold in post-addicts. J Clin Invest. 1943;22:511–6.
De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991;47:337–9.
Sjøgren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain. 1993;55:93–7.
Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 2001;90:91–6.
Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93:409–17.
Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain. 2006;7:43–8.
Woolf CJ. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res. 1981;209(2):491–5.
Cérèlier E, Rivat C, Jun Y, et al. Long lasting hyperalgesia induced by fentanyl in rats. Anesthesiology. 2000;92:465–72.
Célèrier E, Laulin J-P, Corcuff J-B, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci. 2001;21(11):4074–80.
Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase c. J Neurosci. 1994;14(4):2301–12.
Vanderah TW, Ossipov MH, Lai J, Malan Jr TP, Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain. 2001;92:5–9.
Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Mol Brain Res. 2001;86:56–62.
Li X, Angst MS, Clark JD. Opioid-induced hyperalgesia and incisional pain. Anesth Analg. 2001;93: 204–9.
Chia Y-Y, Liu K, Wang J-J, Kuo M-C, Ho S-T. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth. 1999;46(9):872–7.
Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005;103:147–55.
Crawford MW, Hickey C, Zaarour C, Howard A, Naser B. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth Analg. 2006;102:1662–7.
Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the μ-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003;106:49–57.
Koppert W, Sitti R, Scheuber K, Alsheimer M, Schmelz M, Schüttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by s-ketamine and clonidine in humans. Anesthesiology. 2003;99:152–9.
Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg. 2003;97:810–5.
Chen L, Malarick C, Seefeld L, Wang S, Houghton M, Mao J. Altered quantitative sensory testing outcome in subjects with opioid therapy. Pain. 2009;143:65–70.
Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain – new perspective of opioid-induced hyperalgesia. Pain. 2009;139:431–8.
Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001;63:139–46.
Compton P, Kehoe P, Sinha K, Torrington MA, Ling W. Gabapentin improves cold-pressure pain responses in methadone-maintained patients. Drug Alcohol Depend. 2010;109:213–9.
Pud D, Cohen D, Lawental E, Eisenberg E. Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend. 2006;82:218–23.
Hay JL, White JM, Bochner F, Somogyi AA, Semple TJ, Rounsefell B. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J Pain 2009;10(3): 316–22.
Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003;26(2):769–75.
Wilson GR, Reisfield GM. Morphine hyperalgesia: a case report. Am J Hosp Palliat Care. 2003;20:459–61.
Davis MP, Shaiova LA, Angst MS. When opioids cause pain. J Clin Oncol. 2007;25(28):2297–8.
Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008;9(6):724–7.
Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991;251:85–7.
Marek P, Ben Eliyahu S, Gold M. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 1991;547:81–8.
Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain. 1995;61:353–64.
Mao J. NMDA and opioid receptors: their interactions in anti-nociception tolerance and neuroplasticity. Brain Res Rev. 1999;30:289–304.
Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002;22:8312–23.
Narita M, Mizoguchi H, Nagase M, Suzuki T, Tseng LF. Involvement of spinal protein kinase C gamma in the attenuation of opioid-mu-receptor mediated G-protein activity after chronic intrathecal administration of [D-Ala2, N-Mephe4, Gly-Ol5] enkephalin. J Neurosci. 2001;21:3715–20.
Zeitz KP, Malmberg AB, Gilbert H, Basbaum AL. Reduced development of tolerance to the analgesic effect of morphine and clonidine in PKC gamma mutant mice. Pain. 2002;94:245–53.
Mao J, Sung B, Ru Rong J, Grewo L. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 2002;22:7650–61.
Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005;80:319–24.
Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000;20:7074–9.
Campillo A, González-Cuello A, Cabañero D, Garcia-Nogales P, Asunción R, Milanés MV, et al. Increased spinal dynorphin levels and phosphor-extracellular signal-regulated kinases 1 and 2 and c-fos immunoreactivity after surgery under remifentanil anesthesia in mice. Mol Pharmacol. 2010;77(2):185–94.
Chu LF, Dairmont J, Zamora AK, Young CA, Angst MS. The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia. J Pain. 2011;12(1):108–11.
Barbaro NM, Heinricher MM, Fields HL. Putative pain modulating neurons in the rostral ventral medulla: reflex-related activity predicts effects of morphine. Brain Res. 1986;366:203–10.
Heinricher MM, Morgan MM, Fields HL. Direct and indirect actions of morphine on medullary neurons that modulate nociception. Neuroscience. 1992;48:533–43.
Morgan MM, Heinricher MM, Fields HL. Circuitry linking opioid-sensitive nociceptive modulatory systems in periaqueductal gray and spinal cord with rostral ventromedial medulla. Neuroscience. 1992;47(4):863–71.
Vanderah TW, Suenaga NMH, Ossipov MH, Malan Jr TP, Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001;21(1):279–86.
Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci. 2002;22(15):6747–55.
King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005;116:276–88.
White F, Wilson N. Opiate-induced hypernociception and chemokine receptors. Neuropharmacology. 2010;58:35–7.
Gris P, Gauthier J, Cheng P, Gibson DG, Gris D, Laur O, et al. A novel alternative spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain. 2010;6:33–42.
Waxman AR, Arout C, Caldwell M, Dahan A, Kest B. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice. Neurosci Lett. 2009;462(1):68–72.
Van Dorp ELA, Kest B, Kowalczyk WJ, Morariu AM, Waxman AR, Arout CA, et al. Morphine-6b-glcoronide rapidly increases pain sensitivity independently of opioid receptor activity in mice and humans. Anesthesiology. 2009;110:1356–63.
Juni A, Klein G, Kest B. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems. Brain Res. 2006;1070:35–44.
Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, et al. Evidence that intrathecal morphine-3-glucoronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1β. Neuroscience. 2010;165(2):569–83.
Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high dose opioids. J Opioid Manag. 2006;2:277–82.
Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005;22(4):291–4.
Okon TR, George ML. Fentanyl-induced neurotoxicity and paradoxic pain. J Pain Symptom Manage. 2008;35(3):327–33.
Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304–15.
Ebert B, Thorkildsen C, Andersen S, Christru LL, Hjeds H. Opioid analgesics as noncompetetive N-methyl_D-aspartate (NMDA) antagonists. Biochem Pharmacol. 1998;56:553–9.
Blackburn D, Somerville E, Squire J. Methadone: an alternative conversion regime. Eur J Palliat Care. 2002;9(3):93–6.
Axelrod DJ, Reville B. Using methadone to treat opioid-induced hyperalgesia and refractory pain. J Opioid Manag. 2007;3(2):113–4.
Richebé P, Rivat C, Laulin J-P, Maurette P, Simonnet G. Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats. Anesthesiology. 2005;102:421–8.
Minville V, Fourcade O, Girolami J-P, Tack I. Opioid-induced hyperalgesia in a mice model of orthopaedic pain: preventive effect of ketamine. Br J Anaesth. 2010;104(2):231–8.
Forero M, Chan PSL, Restrepo-Garces CE. Successful reversal of hyperalgesia/myoclonus complex with low-dose ketamine infusion. Pain Pract. 2011. doi:10.1111/j.1533-2500.2011.00475.x.
Van Elstraete AC, Sitbon P, Mazoit J-X, Benhamou D. Gabapentin prevents delayed and long-lasting hyperalgesia induced by fentanyl in rats. Anesthesiology. 2008;108:484–94.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Sørensen, J., Sjøgren, P. (2013). Opioid-Induced Hyperalgesia. In: Hanna, M., Zylicz, Z. (eds) Cancer Pain. Springer, London. https://doi.org/10.1007/978-0-85729-230-8_10
Download citation
DOI: https://doi.org/10.1007/978-0-85729-230-8_10
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-229-2
Online ISBN: 978-0-85729-230-8
eBook Packages: MedicineMedicine (R0)